These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18043696)

  • 1. Design of the "Thorough QT Study".
    Darpo B; Sager P
    Clin Pharmacol Ther; 2008 Apr; 83(4):529; author reply 530. PubMed ID: 18043696
    [No Abstract]   [Full Text] [Related]  

  • 2. Sample size calculations in thorough QT studies.
    Zhang L; Dmitrienko A; Luta G
    J Biopharm Stat; 2008; 18(3):468-82. PubMed ID: 18470756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
    Sethuraman V; Sun Q
    Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On power and sample size calculation for QT studies with recording replicates at given time point.
    Chow SC; Cheng B; Cosmatos D
    J Biopharm Stat; 2008; 18(3):483-93. PubMed ID: 18470757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculation for cluster randomized cross-over trials.
    Giraudeau B; Ravaud P; Donner A
    Stat Med; 2008 Nov; 27(27):5578-85. PubMed ID: 18646266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample sizes for clinical trials with normal data.
    Julious SA
    Stat Med; 2004 Jun; 23(12):1921-86. PubMed ID: 15195324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Atkinson AC
    Stat Med; 2009 Dec; 28(30):3739-41; discussion 3759-60. PubMed ID: 19967753
    [No Abstract]   [Full Text] [Related]  

  • 8. Commentary on 'Designs of dose-escalation trials with quantitative responses'.
    Haines LM
    Stat Med; 2009 Dec; 28(30):3742-4; discussion 3759-60. PubMed ID: 19967751
    [No Abstract]   [Full Text] [Related]  

  • 9. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.
    Meng Z; Kringle R; Chen X; Zhao PL
    J Biopharm Stat; 2010 May; 20(3):563-77. PubMed ID: 20358436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonrandomized quality improvement intervention trials might overstate the strength of causal inference of their findings.
    Li LC; Moja L; Romero A; Sayre EC; Grimshaw JM
    J Clin Epidemiol; 2009 Sep; 62(9):959-66. PubMed ID: 19211223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counterpoint: alternative trial designs for antifungal drugs--time to talk.
    Powers JH
    Clin Infect Dis; 2001 Jul; 33(1):107-9. PubMed ID: 11389502
    [No Abstract]   [Full Text] [Related]  

  • 12. Powering our way to the elusive side effect: a composite outcome 'basket' of predefined designated endpoints in each organ system should be included in all controlled trials.
    Tugwell P; Judd MG; Fries JF; Singh G; Wells GA
    J Clin Epidemiol; 2005 Aug; 58(8):785-90. PubMed ID: 16018913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplicity adjustment big and small in clinical studies.
    Hsu JC
    Clin Pharmacol Ther; 2010 Aug; 88(2):251-4. PubMed ID: 20592727
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac repolarization and the safety of new drugs defined by electrocardiography.
    Morganroth J
    Clin Pharmacol Ther; 2007 Jan; 81(1):108-13. PubMed ID: 17186008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The N-of-1 trial: the ideal study design that is underused].
    Vandenbroucke JP
    Ned Tijdschr Tandheelkd; 2007 Jun; 114(6):260-2. PubMed ID: 17695213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Questioning the methodological superiority of 'placebo' over 'active' controlled trials.
    Enkin MW
    Am J Bioeth; 2009 Sep; 9(9):66-7. PubMed ID: 19998202
    [No Abstract]   [Full Text] [Related]  

  • 17. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and analysis of non-inferiority mortality trials in oncology.
    Carroll K; Milsted B; Lewis JA
    Stat Med; 2004 Sep; 23(17):2771-4; author reply 2774-8. PubMed ID: 15316946
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian approach to assay sensitivity analysis of thorough QT trials.
    Dong X; Ding X; Tsong Y
    J Biopharm Stat; 2013; 23(1):73-81. PubMed ID: 23331222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.